Edition:
United States

Valeant Pharmaceuticals International Inc (VRX.N)

VRX.N on New York Stock Exchange

15.08USD
7 Dec 2016
Change (% chg)

$-0.55 (-3.52%)
Prev Close
$15.63
Open
$15.36
Day's High
$15.38
Day's Low
$14.82
Volume
2,129,874
Avg. Vol
3,549,519
52-wk High
$119.85
52-wk Low
$13.77

Summary

Name Age Since Current Position

Joseph Papa

60 2016 Chairman of the Board, Chief Executive Officer

Paul Herendeen

60 2016 Chief Financial Officer, Executive Vice President - Finance

Pavel Mirovsky

65 2013 President, General Manager, Europe

Christina Ackermann

2016 Executive Vice President, General Counsel

Thomas Appio

2016 Executive Vice President, President - Asia Pacific

Ari Kellen

52 2014 Executive Vice President, Company Group Chairman

Robert Rosiello

58 2016 Executive Vice President - Corporate Development and Strategy

Anne Whitaker

49 2015 Executive Vice President

Louis Yu

65 2016 Chief Quality Officer, Global Quality

Thomas Ross

65 2016 Lead Independent Director

William Ackman

49 2016 Independent Director

Fredric Eshelman

67 2016 Independent Director

Stephen Fraidin

76 2016 Independent Director

D. Robert Hale

31 2015 Independent Director

Robert Ingram

73 2016 Independent Director

Argeris Karabelas

63 2016 Independent Director

Sarah Kavanagh

59 2016 Independent Director

Robert Power

59 2008 Independent Director

Russel Robertson

68 2016 Independent Director

Amy Wechsler

46 2016 Independent Director

Laurie Little

Senior Vice President, Investor Relations

Biographies

Name Description

Joseph Papa

Mr. Joseph C. (Joe) Papa serves as Chairman of the Board, Chief Executive Officer of the Company. Mr. Papa has been serving on the Board since May 2016 as chairman and chief executive. He has more than 35 years of experience in the pharmaceutical, healthcare and specialty pharmaceutical industries, including 20 years of branded prescription drug experience. He was CEO of Perrigo Company since 2006 and was appointed chairman in 2007. He resigned from all positions at Perrigo in April 2016. Prior to Perrigo, Papa served as chairman and chief executive officer of Cardinal Health’s Pharmaceutical Technologies and Services business unit (2004 – 2006). He was president and chief operating officer for Watson Pharmaceuticals (2001 – 2004), president of Global Country Operations for Pharmacia’s North American business (2000-2001) and president of Searle’s U.S. Operations (1997-2000). Prior to Searle/Pharmacia, Papa served in a variety of general management, sales, marketing and R&D positions during his 15-year career at Novartis Pharmaceuticals (1983-1997). During his pharmaceutical industry career, he led teams that successfully launched several blockbuster pharmaceutical products including Lotrel, Diovan and Celebrex, and is the patent holder for a cardiovascular combination treatment containing Amlodipine and Benazepril. He is a past member of the UConn Foundation Board of Directors and currently serves on the Smith & Nephew Board of Directors, where he also serves as chairman of the Remuneration Committee. Papa holds a BS in pharmacy from the University of Connecticut and an MBA from Northwestern University’s Kellogg Graduate School of Management. In 2012, he received an Honorary Doctor of Science degree from the University of Connecticut School of Pharmacy.

Paul Herendeen

Mr. Paul S. Herendeen is Chief Financial Officer, Executive Vice President - Finance of Valeant Pharmaceuticals International, Inc. Prior to joining Valeant, he served as Executive Vice President and Chief Financial Officer of Zoetis Inc. for two years. From 2005 to 2013 and from 1998 to 2001, Mr. Herendeen served as CFO at Warner Chilcott, a specialty pharmaceuticals company. He rejoined Warner Chilcott after four years as EVP and CFO of MedPointe, a privately held health care company, where he served as CFO from 2001 until 2005. Prior to that, Mr. Herendeen spent nine years as a principal investor at both Dominion Income Management and Cornerstone Partners, where he worked on investments as well as mergers and acquisitions for the firms and their portfolio companies. He also spent the early part of his career in banking and public accounting, having held various positions with the investment banking group of Oppenheimer & Company, the capital markets group of Continental Bank Corporation, and as a senior auditor with Arthur Andersen & Company. Mr. Herendeen earned a Master of Business Administration (MBA) from the University of Virginia's Darden School of Business, and holds a bachelor's degree in Business Administration from Boston College.

Pavel Mirovsky

Dr. Pavel Mirovsky is a President, General Manager, Europe of Valeant Pharmaceuticals International, Inc. Dr. Pavel Mirovsky was appointed to Valeant's Executive Management Team in April 2013. A medical doctor by training, he has had a distinguished business career. Prior to joining PharmaSwiss, Dr. Mirovsky served as regional General Manager at IMS for Central & Eastern Europe, Near East/ Middle East, North Africa, Benelux, Nordics and Portugal. Prior to IMS, he was President and CEO of Polpharma and also led Aventis' operations in MENA and CEE in senior regional operational roles including Poland and the Baltics. Dr. Mirovsky began his career in the pharmaceutical industry at Rhone Poulenc Rorer, Czech Republic. He worked as an expert for the World Health Organization in Africa, as a visiting scientist at Harvard Medical School and as an assistant professor at University d'Oran in Algeria. He obtained his MD, PhD, and Associate Professor degree from the Charles University in Prague and an MBA from the IFTG Prague. After graduation, he served in several positions at the Academy of Sciences and Postgraduate Medical School.

Christina Ackermann

Ms. Christina Ackermann is Executive Vice President, General Counsel of the Company. Prior to joining Valeant Ms. Ackermann was part of the Novartis group of companies for the past 14 years, most recently serving as Senior Vice President, General Counsel for Alcon where she was responsible for the Legal, Intellectual Property and Compliance functions. Prior to this, she served as Global Head, Legal and General Counsel at Sandoz, the generics division of Novartis, from 2007 to 2012. She joined Novartis Pharma in 2002 as Head, Legal Technical Operations and Ophthalmics and assumed the role of Head Legal General Medicine in July 2005. Before Novartis, Ms. Ackermann served in Associate General Counsel roles with Bristol Myers Squibb and DuPont Pharmaceuticals, as well as in private practice, where she focused on securities and mergers & acquisitions. Christina has a Post Graduate Diploma in EC Competition Law from the University ofLondon, U.K.and a Bachelor of Laws from Queen's University, Kingston, Canada.

Thomas Appio

Mr. Thomas Appio serves as Executive Vice President, President - Asia Pacific of the Company. Thomas Appio was named Executive Vice President/President, Asia Pacific in April 2016. Mr. Appio joined Valeant from Bausch + Lomb in 2013, and under his leadership Valeant has experienced accelerated growth in revenue and profitability in the region, particularly in China. During his four years with Bausch + Lomb, Mr. Appio served as Vice President, North Asia/Japan and as Managing Director, Greater China. Previous to joining Bausch + Lomb, Mr. Appio served 23 years with Schering-Plough in a wide range of leadership and operations responsibilities. Mr. Appio has spent nearly 18 years working in the Asia Pacific region.

Ari Kellen

Dr. Ari S. Kellen has been appointed as Executive Vice President, Company Group Chairman of the Company., with effective January 1, 2014. Dr. Kellen joined Valeant in January 2014. He is responsible for the U.S. Dermatology, U.S. Bausch + Lomb and Latin American businesses. Previously he spent 22 years with McKinsey & Company, where he led growth and turnaround strategies for medical device, pharmaceutical and healthcare services clients. Prior to joining McKinsey, Dr. Kellen worked in senior hospital management and emergency trauma in South Africa. He received his MBBCh and MBA degrees from the University of the Witwatersrand in South Africa.

Robert Rosiello

Mr. Robert L. Rosiello is Executive Vice President - Corporate Development and Strategy of the Company. He was Chief Financial Officer, Executive Vice President of the Company. effective as of July 1, 2015. He worked for 30 years at McKinsey & Company, helping healthcare technology and consumer companies deliver growth through mergers and acquisitions, as well as business unit financial performance improvement. As Senior Partner in charge of the global merger practice for a decade, Mr. Rosiello led M&A integrations for pharmaceutical, specialty pharmaceutical and medical device companies in the U.S., Europe and Asia. He serves on the Board of Catholic Charities of New York, the Pew Research Center and the Central Selection Committee of the Morehead Cain Foundation. Mr. Rosiello received his BA in economics from the University of North Carolina, where he was a Morehead Scholar. He also earned an MS from the London School of Economics and an MBA from Harvard.

Anne Whitaker

Ms. Anne C. Whitaker serves as Executive Vice President, Company Group Chairman of the Company. Anne Whitaker was named Executive Vice President/Company Group Chairman in May 2015. Ms. Whitaker most recently served as President, Chief Executive Officer and a member of the Board of Directors of Synta Pharmaceuticals Corp., a biopharmaceutical company focused on research, development and commercialization of novel oncology medicines. During her time as CEO, Ms. Whitaker was recognized for her work in streamlining the organization and prioritizing its rich pipeline opportunities. Prior to joining Synta Pharmaceuticals, she served as President, North America Pharmaceuticals, at Sanofi, where she oversaw all pharmaceutical and consumer healthcare operations within the region. Previously, Ms. Whitaker held various leadership positions at GlaxoSmithKline, including Senior Vice President and Business Unit Head, Cardiovascular, Metabolic and Urology and Senior Vice President of Leadership and Organization Development.

Louis Yu

Dr. Louis W. Yu, PhD., Chief Quality Officer, Global Quality of the Company., effective Oct. 3, 2016. Dr. Yu joined Valeant from AMRI where he was Senior Vice President, Global Quality and Compliance. From November 2006 to January 2016, he served as Executive Vice President, Global Quality and Compliance at The Perrigo Company, where he was responsible for strategic leadership and regulatory compliance as well as the global patient safety/medical affairs departments. Previously, he served as the highest quality officer for CV Therapeutics, Forest Laboratories and Solvay Pharmaceuticals USA. Earlier in his career, he served in the Quality and R&D organizations for over 16 years at various Johnson & Johnson companies in positions of increasing responsibility. He has been an adjunct professor at the School of Pharmacy, the University of Wisconsin, and currently is an adjunct faculty at the Purdue Polytechnic Institute in West Lafayette. Dr. Yu earned a B.S. in chemistry from the University of Wisconsin, and a M.S. and Ph.D. in analytical chemistry from Rutgers University.

Thomas Ross

Mr. Thomas W. Ross, Sr. is Lead Independent Director of the Company. Mr. Ross has been serving on the Board since March 2016. In June 2016 he was named Lead Independent Director. Mr. Ross is the President Emeritus of the 17-campus University of North Carolina having served as President from 2011-2016. He currently serves as the Sanford Distinguished Fellow in Public Policy at the Duke University Sanford School of Public Policy and as a Professor of Public Law and Government at the UNC Chapel Hill School of Government. Prior to becoming President of the UNC System, Mr. Ross served as President of Davidson College, executive director of the Z. Smith Reynolds Foundation, director of the North Carolina Administrative Office of the Courts, a Superior Court judge, chief of staff to a U. S. Congressman, a member of a Greensboro, NC law firm and as an Assistant Professor of Public Law and Government at UNC-Chapel Hill’s School of Government. Mr. Ross holds a bachelor’s degree in political science from Davidson College (1972) and graduated with honors from the UNC-Chapel Hill School of Law (1975). Mr. Ross currently serves several boards and has received numerous awards and accolades for his public service and professional achievements.

William Ackman

Mr. William A. (Bill) Ackman is Independent Director of the company. Mr. Ackman has been serving on the Board since March 2016. He is the founder and Chief Executive Officer of Pershing Square Capital Management. Mr. Ackman currently serves as a member of the board of Canadian Pacific Railway Limited, chairman of the board of The Howard Hughes Corporation, a trustee of the Pershing Square Foundation, a member of the Board of Trustees at The Rockefeller University and a member of the Board of Dean’s Advisors of the Harvard Business School. Mr. Ackman holds an M.B.A. from Harvard Business School and a Bachelor of Arts magna cum laude from Harvard College.

Fredric Eshelman

Dr. Fredric N. (Fred) Eshelman serves as Independent Director of the company. Dr. Eshelman has been serving on the Board since March 2016 and has more than 35 years of strategic development, executive, operational and financial leadership experience in the pharmaceutical and healthcare industries. He is the founder and former Chief Executive Officer and Executive Chairman of Pharmaceutical Product Development, Inc. (PPD), a global contract pharmaceutical research organization providing drug discovery, development and lifecycle management services. Dr. Eshelman was also the founding chairman of Furiex Pharmaceuticals, Inc., a drug development company that collaborated with pharmaceutical and biotechnology companies to increase the value of their drug candidates by applying an accelerated approach to drug development.

Stephen Fraidin

Mr. Stephen Fraidin serves as Independent Director of the company. Mr. Fraidin has been serving on the Board since March 2016. He joined Pershing Square Capital Management, L.P. in 2015 as Vice Chairman. Prior to joining Pershing Square, Mr. Fraidin was a Senior Partner at Kirkland & Ellis LLP and advised major companies and investment firms in acquisitions, mergers, proxy contests, corporate governance engagements and other matters. He received his LL.B. from Yale Law School and his A.B. from Tufts University. Mr. Fraidin is widely recognized as one of the country’s leading M&A lawyers. He was named to the Financial Times’ top ten most innovative lawyers in North America; The International Who’s Who of Mergers & Acquisitions Lawyers top ten “Most Highly Regarded Individuals;” Law360 MVP of the Year for M&A in 2013, and twice as The American Lawyer’s “Dealmaker of the Year.”

D. Robert Hale

Mr. D. Robert Hale serves as Independent Director of the Company. Mr. Hale has been serving on the Board since August 2015. He is a partner of ValueAct Capital, a governance-oriented investment fund that invests in a concentrated portfolio of public companies and works actively with executives and boards of directors on issues of strategy, capital structure, mergers and acquisitions, and talent management. Prior to joining ValueAct Capital in January 2011, Mr. Hale was a Principal with The Parthenon Group, working in both the Boston and Mumbai offices of Parthenon’s strategic consulting practice, as well as in an investment role at Parthenon’s long-short public equity vehicle, Strategic Value Capital. Mr. Hale is also a director of MSCI, Inc. He has an A.B., cum laude, from Dartmouth College.

Robert Ingram

Mr. Robert A. (Bob) Ingram serves as Independent Director of the Company. Mr. Ingram has been serving on the Board of the Company since September 2010, was the Lead Director from September 2010 to December 2010, was the Chairman of the Board from December 2010 to March 2011, and then Lead Director. In February 2016 he was named Chairman of the Board again. Since January 2007, Mr. Ingram has been a general partner at Hatteras Venture Partners, a venture capital firm with a focus on biopharmaceuticals, medical devices, diagnostics and related opportunities in human medicine. Since January 2010, he has served as a special advisor to the Chief Executive Officer of GlaxoSmithKline. He served as Vice Chairman Pharmaceuticals of GSK from 2002 through 2009 and Chief Operating Officer and President of Pharmaceutical Operations, CEO of Glaxo Wellcome plc from October 1997 to December 2000 and chairman of the board of Glaxo Wellcome Inc., Glaxo Wellcome plc’s U.S. subsidiary, from January 1999 to December 2000. Mr. Ingram was President and CEO of Glaxo Wellcome Inc. from October 1997 to January 1999. Mr. Ingram is also a member of the Board of Advisors for the H. Lee Moffitt Cancer Center and Research Triangle Institute, as well as Chairman of the Board, Research Triangle Foundation of North Carolina and Glaxo North Carolina Foundation. He is a former chairman of the board of Elan Corporation, plc and a former director of Allergan Inc., Misys plc, Nortel Networks Corporation, Wachovia Corporation, OSI Pharmaceuticals, Inc., Lowe’s Companies, Pharmaceuticals Product Development Inc, and Valeant Pharmaceuticals International, which was merged into the Company, then known as Biovail Corporation, in September 2010 at which time the Company changed its name to Valeant Pharmaceuticals International, Inc.

Argeris Karabelas

Dr. Argeris (Jerry) N. Karabelas, Ph.D., serves as Independent Director of the Company. Dr. Karabelas has been serving on the Board since June 2016. Since December 2001, Dr. Karabelas has been a Partner at Care Capital, LLC, a life sciences venture firm. Prior to Care Capital, he was the founder and Chairman at Novartis BioVenture Fund. He served as Head of Healthcare and CEO of worldwide pharmaceuticals for Novartis Pharma AG from 1998 to 2000, with responsibilities for Novartis Pharma, Ciba Vision, Generics and strategic and operational leadership of R&D. Before joining Novartis, Dr. Karabelas was Executive Vice President of SmithKline Beecham responsible for U.S. and European operations, regulatory and strategic marketing. He has served on several boards of pharmaceutical and therapeutics companies, including Renovo, plc; Vanda Pharmaceuticals, Inc.; NitroMed, Inc.; SkyePharma, plc; Human Genome Sciences; and Inotek Pharmaceuticals.

Sarah Kavanagh

Ms. Sarah B. Kavanagh is Independent Director of the Company. Ms. Kavanagh has been serving on the Board since July 2016. From June 2011 through May 2016, she served as a Commissioner, and since 2014 as Chair of the Audit Committee, at the Ontario Securities Commission. She is currently a director and Chair of the Audit Committee of Hudbay Minerals Inc. and a Trustee and Chair of the Compensation and Governance Committee of WPT Industrial REIT. In addition to her public company directorships, she is a director and Chair of the Audit Committee at the American Stock Transfer & Trust Company LLC and the Canadian Stock Transfer Company, a director and Chair of the Audit and Investment Committee of Sustainable Development Technology Canada, and a director of Canadian Tire Bank. Between 1999 and 2010, Ms. Kavanagh served in various senior investment banking roles at Scotia Capital Inc., including Vice-Chair and Co-Head of Diversified Industries Group, Head of Equity Capital Markets, Head of Investment Banking. Prior to Scotia Capital, she held several senior financial positions with operating companies. She started her career as an investment banker with a bulge bracket firm in NY. Ms. Kavanagh graduated from Harvard Business School with a Masters of Business Administration and received a Bachelor of Arts degree in Economics from Williams College. She completed the Directors Education Program at the Institute of Corporate Directors in May 2011.

Robert Power

Mr. Robert N. Power serves as an Independent Director of Valeant Pharmaceuticals International Inc., since August 2008. Mr. Power was a faculty member at The Wharton School of Business, University of Pennsylvania, where he taught multinational marketing from 2009 to 2011. Mr. Power has over 25 years’ experience working in the pharmaceutical and biotechnology industry through a number of leadership positions with Wyeth beginning in 1985 through 2007, including Director, New Product Development; Managing Director, U.K./Ireland; Vice President, Global Marketing; President, Europe, Middle East, Africa; President, International; and Executive Vice President, Global Business Operations. Mr. Power also has completed the Director Professionalism course offered by the National Association of Corporate Directors.

Russel Robertson

Mr. Russel C. (Russ) Robertson serves as Independent Director of the Company. Mr. Robertson has been serving on the Board since June 2016. He has served as Executive Vice President and Head, Anti-Money Laundering, at BMO Financial Group, a diversified financial services organization, since July 2013. Prior to his current role, he served as Executive Vice President, Business Integration and as Vice Chair at BMO Financial Group. He joined the company as Interim Chief Financial Officer in March 2008 and was appointed Chief Financial Officer in August 2009. Before joining BMO, Mr. Robertson held various senior positions with a number of major accounting firms, including Vice Chair, Deloitte & Touche, LLP in Toronto, from 2002 to 2008, and Canadian Managing Partner, Arthur Andersen, LLP, from 1994 to 2002. Mr. Robertson holds a Bachelor of Arts degree (Honours) from the Ivey School of Business at the University of Western Ontario. Since June 2012, Mr. Robertson has served on the boards of Turquoise Hill Resources and Virtus Investment Partners, Inc.

Amy Wechsler

Dr. Amy B. Wechsler, M.D., serves as Independent Director of the Company. Dr. Wechsler has been serving on the Board since June 2016. She has been a practicing dermatologist in New York City since 2005. Dr. Wechsler is the author of the Mind-Beauty Connection, published in 2008. She is board certified in dermatology and psychiatry and is also an Adjunct Clinical Professor in Psychiatry at the Weill Cornell Medical College. As an expert on skin health, Dr. Wechsler is an active member of several medical professional organizations, including the American Academy of Dermatology; the American Psychiatric Association; the American Academy of Child and Adolescent Psychiatry; the Independent Doctors of New York; The Physicians Scientific Society; and The Skin Cancer Foundation. Dr. Wechsler completed her residency in psychiatry and a fellowship in child and adolescent psychiatry at New York Presbyterian Hospital’s Payne Whitney Clinic. She also completed a residency in dermatology at SUNY Downstate Medical Center.

Laurie Little